Parenteral Combination Therapy For Infective Conditions With Drug Resistant Bacterium

ABSTRACT

The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium.

FIELD OF THE INVENTION

The present invention relates to a pharmaceutical composition as amethod of treatment of non-ocular infective conditions for use againstmulti drug resistant bacteria. The particular of the invention disclosesa pharmaceutical composition containing two different antibiotics, aglycopeptide and a cephalosporin, combined with the help of at least onesolubilizing/stabilizing agent and is present in dry powder form. Themethod of treatment disclosed by the invention follows a parenteralroute of administration after reconstitution with a suitable solvent.

1. Background of the Invention

Use of antibacterial agents has grown rapidly over the past few yearsand so has the resistance of bacterial strains to antibiotics that usethese agents as detailed by Sharma Rashmi et al; Indian J Med Sci 2005in their article: “Antibacterial resistance: Current problems andpossible solutions”. New range of bacterial strains that are resistantto multiple drugs has also evolved.

Penicillin, which is the first known antibiotic, has exhibited anexcellent efficacy toward Staphylococci. However, penicillin resistantbacteria that degrade penicillin, emerged with the period of time.Research and development of penicillinase resistant penicillins (PRP)such as methicillin and cephems antibiotics provided solutions inclinical aspects to many problems posed by the penicillin resistantbacteria.

However, in recent years, as a result of overuse and misuse ofthird-generation cephem antibiotics, which have weak antibacterialpotency on staphylococci and which are resistant to these antibioticshave selectively proliferated. Such bacteria have come to spread inhospitals, leading to rise in number of cases of hospital acquiredinfections. In particular, methicillin-resistant Staphalococcus aureusbacteria, commonly known as MRSA, has emerged, against which all knownbeta-lactam agents are ineffective. MRSA is an example ofmultiple-drug-resistant bacteria that are broadly resistant to not onlypenicillin antibiotics but also cephem antibiotics and aminoglycosideantibiotics individually. Examples of currently used antibiotics againstMRSA infections include formulations containing glycopeptides such asvancomycin (VCM) and the like. However, VCM is involved in resistance tobacteria such as MRSA as discussed in ‘Emergence of low level vancomycinresistance in MRSA’ by Assadullah S et al 2003.

In addition, combinations of multiple antibiotics have beenconventionally investigated aiming at the enhancement of antibacterialpotency in an article ‘Re-emerging Staphylococci Infections’ by BarryKreiswirth. Therefore, there exists an urgent need to the development ofnovel antibacterial combination drugs which are effective on resistantbacteria and can act synergistically as is done in the invention.

There have been many attempts to combat broad-spectrum gram negative andgram positive bacteria. These include administration of multipleantibacterial agents such as vancomycin and ceftriaxone. Ceftriaxone isless active against gram positive cocci than first generationcephalosporin. However, it is markedly active against gram negativebacteria such as Enterobacteriaceae including beta lactamase producingstrains and penicillin resistant strains such as Haemophilus influenzae,Neisseria gonorrhoeaea and N. meningitis. It is also active againstStaphylococcus aureus including penidllinase producing strains but notagainst methicillin resistant Staphylococcus aureus. Whereas vancomycinacts against variety of gram positive bacteria including methicillinresistant Staphylococcus aureus and Staph. epidermidis. Vancomycin showshigh level acquired transferable resistance against Enterococci whichappears to be plasmid mediated.

The use of multiple antibacterial agents for prevention and treatment ofa variety of infectious disease states are found to be synergistic invitro Ribes S et al J Antimicrob Chemother 2005 in their articleexplained that an additive effect was observed when combinations ofceftriaxone plus vancomycin were studied at sub inhibitoryconcentrations.

The emergence of multidrug-resistant pneumococci and, more recently, ofpneumococci tolerant to vancomycin are important public health concernsworldwide (Henriques Normark et al, Clin. Infect. Dis. 2001; Novak, R,Nature 1999; R. M. Atkinson et al 40th Intersci. Conf. Antimicrob.Agents Chemother., 2000; A. Marchese, et al 40th Intersci. Conf.Antimicrob. Agents Chemother., 2000).

Various earlier investigations show that combination of vancomycin andceftriaxone is more active against bacteria than monotherapy aloneagainst commonly encountered pathogens in bacterial meningitis. VioletaRodriguez-Cerrato, Antimicrob Agents Chemother. 2003; the aims of theirstudy were to assess the bacteriologic effectiveness of these agentsagainst experimental meningitis caused by vancomycin tolerantpneumococci and to compare the results with those obtained byconventional therapy with vancomycin and ceftriaxone in combination.

‘Rifampicin+ceftriaxone versus vancomycin+ceftriaxone in the treatmentof penicillin—and cephalosporin-resistant pneumococcal meningitis in anexperimental rabbit model’ by Suntur B M et al in Int J AntimicrobAgents. 2005 found Ceftriaxone+rifampicin was as effective asceftriaxone+vancomycin.

Kaplan S L (2002) found that ceftriaxone and vancomycin are useful inthe treatment and management of pneumococcal meningitis. Kaplan mentionsthat the standard empiric therapy for suspected bacterial meningitis forinfants and children older than 1 month of age is the combination ofcefotaxime or ceftriaxone and vancomycin. Treatment is modified afterantimicrobial susceptibilities are available.

Jaing, T H, et al, in their 2002 publication reported a treatment ofmeningitis caused by highly-penicillin-resistant Streptococcus mitis ina leukemic child. The paper reported the case of a patient that wassuccessfully treated with a combination of vancomycin, ceftriaxone, andgranulocyte-colony-stimulating factor.

Cottangnoud P et. al. (2002) found that in experimental rabbitmeningitis, cefepime given at a dose of 100 mg/kg was associated withconcentrations in the cerebrospinal fluid of between 5.3 and 10 mg/L anda bactericidal activity of −0.61+/−0.24 Delta log(10) cfu/mL×h, similarto the standard regimen of ceftriaxone combined with vancomycin(−0.58+/−0.14 Delta log(10) cfu/mL×h) in the treatment of meningitis dueto a penicillin- and quinolone-resistant pneumococcal mutant strain (MIC4 mg/L).

Banon et. al. (2001) worked on time-kill evaluation in Spain. In thisstudy the bactericidal activity of four antimicrobial regimens againstten clinical isolates of S. pneumoniae (five with an intermediateresistance to penicillin and five highly resistant ones), was determinedby means of kill kinetics studies using either penicillin, orceftriaxone, in combination with vancomycin, or fosfomycin.

Desbiolles et. al (2001) worked on fractional maximal effect method forin vitro synergy between amoxicillin and ceftriaxone, and betweenvancomycin and ceftriaxone, against Enterococcus faecalis andpenicillin-resistant Streptococcus pneumoniae. They reported anassessment of the use of a new in vitro testing method and graphicalrepresentation of the results to investigate the potential effectivenessof combinations of amoxicillin (AMZ) plus ceftriaxone (CRO), and of CROplus vancomycin (VAN) against strains of Streptococcus pneumoniae (PRPstrains) highly resistant to penicillin and cephalosporins.Consequently, either of the combinations was proposed for use for thetreatment of PRP infections.

Huebner et. al. (2000) reported that ceftriaxone or cefotaxime should beused in combination with vancomycin for the treatment of meningitisuntil a cephalosporin-resistant pneumococcal cause is excluded.

Roos (1999) studied bacterial meningitis therapy using a combination ofthird generation cephalosporins and vancomycin. He has suggested thatinitial empiric therapy for community-acquired bacterial meningitisshould be based on the possibility that penicillin-resistant pneumococcimay be the etiologic organisms and, hence, should include a combinationof third-generation cephalosporin (cefotaxime or ceftriaxone) andvancomycin.

Climo et. al., 1999 found that combinations of vancomycin andbeta-lactams are synergistic against staphylococci with reducedsusceptibilities to vancomycin. Evidence of synergism betweencombinations multiple antibacterial agents such as vancomycin andcephalosporins against 59 isolates of methicillin-resistantstaphylococci (Staphylococcus aureus, Staphylococcus epidermidis, andStaphylococcus haemolyticus) was collected. They concluded that thecombination of vancomycin and beta-lactams with antistaphylococcalactivity is an effective regiment for the treatment of infections withclinical strains of staphylococci which demonstrate reducedsusceptibility to glycopeptides.

In a study of antimicrobial resistance of invasive Streptococcuspneumoniae in Slovenia, 1993-1995, Cizman M et. al. (1997) found thatall penicillin-resistant isolates (intermediate resistance) weresusceptible to cefotaxime, ceftriaxone and vancomycin.

2. Disadvantages of Prior Art

One feature of the references stated above is that each drug of thecombination used in the multiple antibacterial agent treatments reportedtherein was individually administered one after the other withoutspecific or predetermined ratio. Such administration and also theco-administration as mentioned in case of some of the above referenceshave a number of disadvantages. These are as stated here:

-   -   1. Drugs mentioned as the combinations used in the multiple drug        treatment are administered one after the other.    -   2. These drugs are not available in a premixed compositions as        single drug.    -   3. There is complexity involved in administration of the drug as        more number of pricks is required and the time of administration        is also long.    -   4. Treatment time is prolonged to about 14 days in case of        individual administration of these drugs and to about 7 days in        case of co-administration of the composition of invention.    -   5. Cost to the patient is higher due to increased        hospitalization time.    -   6. The failure rate is higher due to inconsistency of dose.        Kazragis et al (1996) have given ceftriaxone at a dose of 25        mg/kg of body weight administered every 12 h and Vancomycin at        30 mg/kg administered every 12 h; Ulla-Stina Salminen et.        al. (1999) have given 2 g dosage of ceftriaxone and 500 mg of        vancomycin iv every 6 h for 48 h.    -   7. Due to non availability of fixed dose at fixed intervals,        chances of development of resistance are very high in case of        prior art.

The individual administration of the Ceftriaxone and vancomycincomponents of drugs described in the prior art fails to solve thetreatment problem satisfactorily because of following reasons:

-   -   (a). The components are administered one after the other and        individually in different doses.    -   (b). The components are administered either in equal proportions        or the ratio is undefined and not fixed.    -   (c). The success rate of such a treatment is not as per the        desired levels.    -   (d). Use of oral route with parenteral route is adopted in some        cases.    -   (e). Co-administration has to be done very carefully as two        individual components are not chemically compatible with each        other.    -   (f). Due to incompatibility of individual components more        precautions are required to be taken like use of different        syringes for individual component and difference in time of        administration of two drugs.

ADVANTAGES OF INVENTION

An essential requirement for successful antibacterial therapy is thatdrug must reach a site of infection at concentrations near or higherthan the minimal inhibitory concentrations. Furthermore, theseconcentrations must be maintained for a certain minimal time as achievedby the composition of invention. The differences in the ability ofvarious antibacterial agents to reach site of infection sometimes havegreater influence on determining the agent for treatment than thedifferences in the agents' intrinsic antibacterial activity.

Parenteral administration is generally the preferred method of drugdelivery in emergency situations, and is also useful in treatingsubjects with digestive tract illnesses or swallowing difficulties, aswell as subjects who are uncooperative, unconscious, or otherwise unableor unwilling to accept oral medication.

Moreover, parenteral routes of administration offer numerous benefitsover oral delivery in many situations, for a wide variety of drugs. Oneadvantage of parenteral administration is that therapeutically effectiveblood serum concentrations of the drug are achieved in a shorter timethan is achievable by other routes of administration. This results inmore rapid onset of therapeutic action and more complete delivery to asite of infection, as compared with other routes of administration suchas oral, transmucosal, transdermal, rectal and vaginal routes. This isespecially true of intravenous injection, whereby the drug is placeddirectly in the bloodstream. Hence the present invention is developed inparenteral form only.

Parenteral administration can also result in more predictable bloodserum concentrations of a drug than oral administration. This is becauselosses in the gastrointestinal tract due to metabolism, partial or totaldegradation of the drug, binding to food, and other causes areeliminated. In addition, the effective use of some antibacterial agentsrequires continuous, controlled administration to achieve the desiredeffect.

Another aspect of parenteral drug theory that has been consideredhitherto is that the parenteral drug products should be inspectedvisually for particulate matter/precipitation and discoloration prior toadministration, whenever possible. Although existing individualformulations exhibit satisfactory clarity when prepared in accordancewith recommended manufacturer's instructions, it is mandatory to furtherreduce and minimize the particulate formations/precipitations that occurin the combining pharmaceutical compositions upon reconstitution as isdone in prior art.

The above mentioned prior art references disclose a number of usefulcompositions. However, there still exists a need in the medical fieldfor pharmaceutical compositions that use multiple antibacterial agentsand also for methods of treatment and prevention for infectiveconditions, using such compositions that:

-   -   (a) ensure rapid delivery of therapeutic agent(s) to the site of        an infective condition,    -   (b) are safe and chemically compatible to each other    -   (c) can be administered easily without posing any medical        hazard,    -   (d) provide effective treatment of the hospitalised patient for        the treatment of bacterial infections and other complications        associated with a non-ocular infective condition,    -   (e) provide efficacy against a wide variety of infectious        organisms,    -   (f) have a potential to administer a lower dose of a therapeutic        agent while still providing efficacy, and    -   (g) have a potential to administer a higher dose of an        antibacterial agent without increased side effects.    -   (h) ensure improvement of the therapeutic index of an active        agent while decreasing its general toxicity and minimizing the        risk of systemic effects.

OBJECTS OF THE INVENTION

Accordingly, the objects of the present invention are described asbelow:

An object of the present invention is to provide pharmaceuticalcompositions that are safe, that have efficacy against a wide variety ofinfectious organisms, and to provide a composition that is useful inproviding effective treatment against non-ocular infective conditions ofa multi drug resistant bacteria.

Yet another object of the present invention is to provide a method oftreatment of non-ocular infective conditions that ensures rapidtherapeutic delivery of therapeutic agent(s) to the site of theinfective condition.

Further object of the present invention is to provide pharmaceuticallyeffective dose for parenteral administration for hospitalized patientswith acute or serious non-ocular infections.

Still another object of the present invention is to provide dosage formsthat have a potential to provide effective treatment without increasedside effects.

A further objective of the present invention is to provide a process ofmaking pharmaceutical compositions of the present invention.

A still further objective of the present invention is to provide achemically compatible stable formulation that is easy to administer.

SUMMARY OF THE INVENTION

The invention describes a pharmaceutical composition to combatmultiple-drug-resistant bacteria in non-ocular infective conditions.Compositions comprising glycopeptides, in particular vancomycin, andcephalosporins, in particular ceftriaxone, are disclosed. Suchcompositions are found to be useful for parenteral administration forhospitalized patients with serious infections. Specifically, thisinvention also discloses a pharmaceutical composition further includingan excipient such as CVMC agent and is available in dry powder form forreconstitution before injection with a suitable solvent.

The pharmaceutical compositions of this invention have been foundnormally to enhance resistance to precipitation in solutions to beadministered parenterally.

The invention also gives details of the dosage forms stored in sealedcontainers to be reconstituted before use. The invention furtherprovides a process to manufacture these compositions and also a methodof treating a subject having non-ocular infective conditions due tomulti drug resistant bacteria.

DEFINITIONS

Some of the various terms used in the description of the invention aredescribed below:

A “non-ocular infective condition” herein is a non-neoplastic disease,disorder or condition of a bodily tissue, organ or system other than aneye or part thereof, that is mediated by a pathogenic bacterium or thatis otherwise responsive to treatment with the antibacterial agents suchas glycopeptides and cephalosporins.

The term, “dose-concentrate” refers to a solution of the pharmaceuticalcomposition. The dose-concentrate may be held in the container where itwas formed by adding suitable solvent or diluent to the pharmaceuticalcomposition. The dose-concentrate is generally further diluted to a unitdosage concentration for administration to a mammal. The entire volumeof the dose-concentrate or aliquots thereof may be used in preparingunit dose(s) for treatment by the method of this invention.

The term “antibacterially effective amount” as used herein refers to anamount of both the antibacterial agents that is sufficient, whenadministered by the method of the invention, to reduce, relieve, preventor delay onset of one or more symptoms of an infective condition beingtreated, or to reduce numbers and/or activity of a causal organism.

The term “treatment” herein includes administration parenterally to asubject that show clinical signs of a non-ocular infective condition, orat risk of developing such an infective condition.

The term “parenteral administration” herein embraces the means ofinjection or infusion of a composition into veins that is intravenouslyonly. For example, administration can be by longer-term infusion. Anyknown device useful for parenteral infusion of a drug can be used toeffect such administration. Parenteral administration herein does notinclude administration solely to the skin surface, such as topical ortransdermal administration. Both the antibacterial agents areadministered parenterally in the method of the invention. Preferredparenteral administration route is intravenous only.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides pharmaceutical compositions containingtwo antibacterial agents both acting as active ingredients, to combatnon-ocular infective conditions corresponding to a single unit/multipledose. The invention also discloses a method of treatment of non-ocularinfective conditions using these compositions. The compositions andmethod of treatment described in the present invention are used againstmultiple-drug-resistant bacteria such as MRSA. The invention alsoprovides a process of manufacturing these compositions. The inventionfurther provides dosage forms stored in sealed containers.

Different embodiments of the present invention are described below.

The preferred embodiment of the present invention basically provides acomposition that is parenterally administrable for combatingmultiple-drug resistant bacteria, comprising:

-   a. an antibacterially effective amounts of a first antibacterial    agent such as a glycopeptide, wherein the glycopeptide is    vancomydin, or a pharmaceutically acceptable salt thereof such as    vancomycin hydrochloride,-   b. an antibacterially effective amount of a second antibacterial    agent such as a cephalosporin wherein the cephalosporin is    ceftriaxone or a pharmaceutically acceptable salt thereof such as    ceftriaxone sodium.

Preferred antibacterial agents applicable for use according to theinvention are beta-lactams and glycopeptides, but not limited to onlybeta-lactam antibacterials such as natural and synthetic penicillin typeagents including penam penicillins (such as benzyl penicillin,phenoxymethyl penicillin, coxacillin, nafcillin, methicillin, oxacillin,amoxycillin, temocillin, ticarcillin and the like), penicillinase-stablepenicillins, acylamino and carboxypenicillins (such as piperacillin,aziocillin, meziocillin, carbenicillin, temocillin, ticarcillin and thelike), and broader spectrum penicillins (such as streptomycin, neomycin,framycetin, gentamicin, apramycin, amikacin, spectinomycin, amoxycillin,ampicillin and the like), cephalosporins (such as ceftriaxone, cefepime,ceftazidime, cefotaxime, cefuroxime and cefaclor) and glycopeptides(such as vancomycin, avoparcin, ramoplanin, teicoplanin and daptomycinand the like).

The antibacterial agents are administered simultaneously or sequentiallyin any order. The pharmaceutical composition according to the preferredembodiment of the invention is in the form of a sterile powder whereinsaid predetermined weight ratio of said first antibacterial agent tosaid second antibacterial agent is in the range from about 1:4 to about4:1 respectively, preferably in the range from about 1:3 to about 3:1respectively, more preferably in the range from about 1:2 to about 2:1respectively that can be reconstituted by addition of a compatiblereconstitution diluent prior to parenteral administration correspondingto a single unit/multiple dose.

Vancomycin hydrochloride is the most preferred form of vancomycin in thecompositions of the present invention. Vancomycin free acid is thepreferred source of vancomycin; produced by the growth of certain strainof Amycolatopsis orientalis (Nocardia orientalis, Streptomycesorientalis) or by any other means; for use in making the compositions ofthe present invention. The free acid may be converted to thehydrochloride salt during the formulation process. Vancomycinhydrochloride is (S_(a))-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-{[2-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-□-L-lyxo-hexopyranosyl)-□-D-glucopyranosyl]oxy}-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro—7,22,28,30,32-pentahydroxy-6-[(2R)-4-methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo-22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]-benzoxadiazacyclotetracosine-26-carboxylicacid, monohydrochloride with a chemical formula of C₆₆H₇₅Cl₂N₉O₂₄, HCland a molecular weight of 1485.7

Ceftriaxone sodium is the most preferred form of ceftriaxone in thecompositions of the present invention. Ceftriaxone free acid is thepreferred source of ceftriaxone for use in making the compositions ofthe present invention. The free acid may be converted to the sodium saltduring the formulation process. Ceftriaxone sodium is(Z)-7-[2-(2-Aminothiazole-4-yl)-2-methoxyiminoacetamido]-3-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-1,2,4-triazin-3-yl)thiomethyl]-3-cephem-4-carboxylicacid, disodium salt, Sesquaterhydrate with a chemical formula ofC₁₈H₁₆N₈Na₂O₇S₃,3.5H₂O and a molecular weight of 661.6.

It has been found that incorporation of a chemical vector agent and asuitable salt thereof into the dry powder composition of the inventionmakes the combination stable after reconstitution. As a furtherembodiment of this invention, the composition of the preferredembodiment further comprises a stabilizing agent such as sodiumbicarbonate or L-arginine wherein the weight of stabilizing agent, is inthe range of about 35% to about 75% of the combined weight of said firstantibacterial agent and said second antibacterial agent.

The pharmaceutical combination of the present invention is alsopresented in a reconstituted form along with a sterile solvent vehiclewith or without, an excipient or a neutralizing agent.

The dosage form of the compositions of the present invention isparenteral. The total said dosage is administered preferably twice a dayto a patient, spread over a period of 12 hours in a day depending uponthe patient condition and severity of infection.

The antibacterial agents may be present in the composition as drugparticles, powders, granules, nanoparticles, microparticulates,microspheres, in lyophilized form and the like.

The suitable solvent vehicle referred to in the invention is preferablyaqueous based. The pharmaceutically acceptable carrier or vehiclereferred to in this invention is one that has no unacceptably injuriousor toxic effect on the subject when administered as a component of acomposition by parenteral administration in an amount required herein.No excipient ingredient of such carrier or vehicle used in thisinvention reacts in a deleterious manner with another excipient or withthe antibacterial agents in the composition.

The antibiotic product composition disclosed in the preferred embodimentof this invention is twice a day product, whereby the administration ofthe antibiotic product is a dose concentrate corresponding to a singleunit/multiple dose and is diluted before administration in suitableinfusions; such as Sterile suitable solvent, 0.9% Sodium Chloride, 5%Dextrose Injection. The preferred regimen is that the product isadministered twice over a twelve hour period.

Particulate formation/precipitation inhibitor of the invention includeethylene diamine tetraacetic acid (EDTA) and salts thereof, astabilizing agent such as sodium bicarbonate, a neutralizing agent, abuffer or a chemical vector. Preferably, the pharmaceutical compositionsdescribed herein have an effective amount of a particulateformation/precipitation inhibitor in the range of about 10% to 40% ofthe total weight of the combination product in the form of a chemicalvector.

In another embodiment of the present invention the composition comprisesa therapeutically effective amount of vancomycin or a pharmaceuticallyacceptable salt thereof such as vancomycin hydrochloride, wherein saidfirst antibacterial agent (vancomycin hydrochloride) is present in saidcomposition at a concentration in the range from about 1 mg/ml to about100 mg/ml, preferably in the range from about 5 mg/ml to about 75 mg/ml,and more preferably in the range of about 10 mg/ml to about 50 mg/ml andceftriaxone or a pharmaceutically acceptable salt thereof such asceftriaxone sodium where in second antibacterial agent (ceftriaxonesodium) is present in said composition at a concentration in the rangefrom about 1 mg/ml to about 200 mg/ml, preferably in the range fromabout 5 mg/ml to about 150 mg/ml, and more preferably in the range fromabout 10 mg/ml to about 100 mg/ml along with an effective amount of aparticulate formation/precipitation inhibitor in the form of a suitablechemical vector which is reconstituted by addition of a sterile solventvehicle. The pH of this embodiment may be maintained within a range ofabout 7.0 to 9.0.

The inventors have found that this composition advantageously overcomesthe bacterial resistance that is experienced by the monotherapydescribed in the prior art. They have discovered that the glycopeptidecomponent of the composition of the present invention provides abactericidal action against a variety of gram positive bacteria, whereasthe cephalosporin elements exhibit a high degree of stability in thepresence of beta-lactamases of both gram positive and gram negativebacteria.

The present invention also provides a novel method of treatment ofnon-ocular infective conditions. The method comprises administering to asubject, by parenteral administration, the composition described in thepreferred embodiment in combination therapy with a suitable solventvehicle. The combination therapy thus described is administered to asubject who has clinical signs of an infective condition. Parenteralmethods of administration are an important option for delivery oftherapeutic agents especially for drugs like vancomycin which are poorlyabsorbed when administered orally, and to which bacterial resistancetends to develop in gastrointestinal tract. Ceftriaxone is alsoadministered through intravenous route effectively.

Combination therapy refers to a treatment regimen wherein the twoantibacterial agents are administered together in such a way as toprovide a beneficial effect from co-action of these therapeutic agents.Such beneficial effect can include, but is not limited to,pharmacokinetic or pharmacodynamic co-action of the therapeutic agents.Combination therapy, for example, results in lowering the dosage of oneor both agents than would normally be administered during monotherapydescribed in the prior art, thus decreasing risk or incidence of adverseeffects associated with higher doses. Alternatively, combination therapyalso results in increased therapeutic effect at the normal dose of eachagent in monotherapy. Furthermore, combination therapy maximizes thetherapeutic effect.

Combination therapy as referred to in this invention does not encompassadministration of two or more therapeutic agents as part of separatemonotherapy regimens that incidentally and arbitrarily result insequential or simultaneous treatment.

They have also found that when administered intravenously, thecombination therapy of the invention provides enhanced treatment optionsas compared to administration of either the antibacterial agent.Combination therapy according to the invention provides effectivetreatment of an infective condition, and reduces the time required toresolve the infective condition caused by bacteria particularly themulti-drug-resistant varieties such as MRSA and Staphylococcal species.It is found by the inventors that the method of treatment disclosed inthis invention also reduces the risk of developing such infectiveconditions. Therefore the combination therapy as described herein can beadministered prior to or following surgery or hospital admission toprevent or reduce the risk of a subject developing an infection causedmainly by MRSA and Staphylococcal species.

In another embodiment of the invention, the antibacterial agentsapplicable for use include any such agents that are effective fortreatment and/or prevention of an infectious condition and/orcomplications associated therewith. The active ingredients used in thecompositions of the present invention include any of the antibacterialagents mentioned above or their pharmaceutically acceptable tautomers,stereoisomers, enantiomers, salts, hydrates, dihydrates, and prodrugs,and are not limited to any one form of the drug.

The inventors have found that the combination therapy as describedherein provides safe, effective treatment for the infectious componentof a non-ocular infective conditions such as meningitis; sepsis;typhoid; abdominal infections (peritonitis, infections of the biliaryand gastrointestinal tracts); infections of the bones, joints, softtissue, and wounds; infections in patients with impaired defensemechanisms; renal and urinary tract infections; respiratory tractinfections, particularly pneumonia, and ear, nose and throat infections;genital infections, including gonorrhoea; lower respiratory tractinfections; skin and skin structure infections; staphylococcalendocarditis. Inventors have also found that in such combination therapyboth active ingredients can act synergistically in the presence ofchemical vector for the treatment of complications associated with abovedescribed conditions.

This invention includes a sterile fixed dose combination available asdose concentrate of two antibacterial agents in antibacteriallyeffective amount useful for treatment of non ocular bacterial infectionsin mammals which when reconstituted generally has reduced particulateformation/precipitation and is chemically compatible and stable.

When making the suitable solvent vehicle a neutralizing agent likeaminocarboxylic acid chelating agent, for exampleethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaaceticacid (DTPA), hydroxyethylenediaminetriaceti-c acid (HEDTA),nitrilotriacetic acid (NTA), is optionally mixed with a desired quantityof water for injection and neutralized with sodium bicarbonate orL-arginine or other suitable agents, to bring the concentration of thesolution within the preferred range of about 10 to about 100 mg/ml, morepreferably within the range of about 20 to about 90 mg/ml, and mostpreferably within the range of about 40 to about 80 mg/ml or anycombination or sub combination of ranges therein.

In another embodiment of the present invention, a pharmaceuticallyeffective unit/multiple dose of said antibiotic combination, in the formof dose concentrate, is provided in a sealed airtight container which isselected from the group consisting of a vial, an ampoule, a syringe, apacket, a pouch and an auto-injector, wherein said container has a headspace volume sufficient for introduction of appropriate volume of asuitable solvent sufficient to form a unit/multiple dose in the form ofan appropriate reconstituted solution of said antibiotic combination.

The head space volume is occupied aseptically by an inert-gas-limitedmicro atmosphere, which comprises essentially one or more inert gaswhich is selected from the group of noble gases and nitrogen; preferablynitrogen, volume of said nitrogen gas being not more than 5% of saidhead space volume, and wherein ratio of said fill volume to said headspace volume is not less than 1:1.

In the present invention, the antibiotic combination is alternativelyprovided in a sealed container such as transparent glass vial cappedwith appropriate halogenated stopper and seal, and is used afterreconstitution for intravenous administration for the treatment of nonocular bacterial infections caused by multi drug resistant bacteria.

According to this invention, the process for the manufacture of apharmaceutical composition as a dose-concentrate in the powder formcontained in sealed container that can be reconstituted prior toadministration, comprises the steps of:

(a) sterile filling/blending two active ingredients, first activeingredient being the vancomycin or the pharmaceutically acceptable saltthereof and second ingredient being the ceftriaxone or thepharmaceutically acceptable salt thereof, adding a particulateformation/precipitation inhibitor present in the form of chemicalvector; the sterile filling/blending being continued for a periodranging from about 1 hour to about 8 hours,(b) proportioning the sterile fill/blend of step (a), aseptically to getdesired dose in weight ratio of said first active ingredient to saidsecond active ingredient in the range from about 4:1 to about 1:4respectively, preferably from about 3:1 to about 1:3 respectively, morepreferably in the range of about 2:1 to about 1:2 respectively, with therange of chemical vector being 10% to 40% of the total weight ofblended/filled composition and(c) capping aseptically with pre or post inert gassing.

Sterilization of the liquid solvent vehicle of the invention can beachieved by any conventional method that preserves the biologicalactivity of the composition, such as by filter sterilization, moist heator steam heat sterilized.

Conditions that can be treated and/or prevented by the method of theinvention include, but are not limited to, disorders caused by grampositive organisms such as Staphylococcus, Micrococcus, Streptococcus,Enterococcus, Leuconostoc, Pediococcus, Stomatococcus, coryneformbacteria, Listerla, Erysipelothrix, Kurthia, Bacillus, Nocardia,Rhodococcus, Gordona, Actinomadura, Streptomyces, Mycobacterium,Colostridium, Peptostreptococcus, Propionibacterum, Lactobacllus,Actinomyces and the like; gram negative organisms such asEnterobacteriaceae, Escherichia, Shigella, Salmonella, Klebsiella,Enterobacter, Citrobacter, Serratia, Yersinia, Vibrio, Aeromonas,Plesiomonas, Pseudomonas, Burkholderia, Stenotrophomonas, Ralstonia,Brevundimonas, Comamonas, Acidovorax, Acinetobacter, Achromobacter,Alcaligenes, Moraxella, Methylobacterium, Actinobacllus, Capnocytophaga,Eiknella, Kingella, Legionella, Neisseria, Branhamella, Haemophilus,Bordetella, Brucella, Pasteurella, Bartonella, Afipia, Francisella,Bacteroides, Porphyromonas, Prevotella, Fusobacterium, Campylobacter,Arcobacter, Helicobacter, Leptospira, Leptonema, Chlamydia, Rickettsia,Coxiella, Ehrlichia and the like; and other infective organismsincluding Treponema, spiochetes, Borrelia, Mycoplasma, Ureaplasma,obligate intercellular bacteria and Anaerobic organisms: Bacteroidesspp. (bile-sensitive)*, Clostridium spp. (excluding C. diffcile),Fusobacterium nucleatum, Fusobacterium spp. (other), Gafflkia anaerobica(formerly Peptococcus), Peptostreptococcus spp. and the like.

Infective conditions for which the method of the invention is usefulinclude, without limitation, bacterial meningitis, soft tissueinfections, infections of the respiratory system including lowerrespiratory tract infections, sinusitis, otolaryngological infections,infections of the gastrointestinal tract (such as gastroenteritis,helicobacter pylori, bacterial diarrhea, bacillary dysentery,extraintestinal infections, intestinal yersiniosis, enteritis, terminalileitis, peptic ulcer disease, gastric ulcer disease, atrophicgastritis, mesenteric lymphadenitis, pseudoappendicitis and the like);infection related to abdominal trauma; pyelonephritis; nocardialpulmonary infections (such as pleural effusion, pericarditis,mediastinitis, superior vena cava obstruction and the like); cutaneousnocardiosis (such as mycetoma, lymphocutaneous infections and the like),skin infections (such as impetigo, erysipelas, cellulitis, skin ulcers,secondary cutaneous involvement with disseminated disease and the like,scalded skin syndrome); leprosy, mycobacterial lymphadenitis, kidneyinfections, malacoplakia, puerperal sepsis, bloodstream infections (suchas typhoid and the like), anthrax, plagues (such as bubonic plague,pneumonic plague, primary and secondary septicemic plague and the like);scarlet fever, rheumatic fever, cholera, Haverhill fever, Potomac fever,brucellosis, Carrion's disease, trench fever, bacillary epithelioidangiomatosis, leptospirosis, Lyme disease, rickettsiosis, Q fever, humanmonocytotropic ehrlichiosis, cat scratch disease, tularemia,pseudo-infections, legionellosis, noscoccomial infections (such asfuruncles, postoperative wound infections of various sites and thelike), erysipeloid, osteomyehtis, prostatitis, peritonitis,encephalitis, cerebrospinal infections, infection of cerebrospinal fluidshunt, meningoencephalitis, infection of the joints, prosthetic jointinfections, septic arthritis, myonecrosis, echyma gangrenosum,cholecystitis, melioidosis, mastoiditis, epididymitis, bursitis,comamonas testosteroni infections, mastitis, cerebritis, abscesses (ofmuscle, urogenital tract, central nervous system, intra-abdominal,intracranial and the like), reproductive tract infections (such asvaginal infections, cervical lymphadenitis, gonorrhea, urethritis,endometritis, postpartum endometritis, perihepatitis, Chlamydiatrachomatis infections, pelvic inflammatory disease, endocervicalinfections, salpingitis, pelvic peritonitis, tubo-ovarian abscesses,chancroid, amnionitis, chorioamnionitis, treponematosis and the like),infections in patients with impaired defense mechanisms.

Experimental Data:

Experimental data in support of the compositions and methods oftreatment proposed in this invention is presented below. It comprisesdata on minimum inhibitory concentration, bacterial susceptibilitytests, stability and cost comparison. Results are presented in Tables 1,2 and 3.

Minimum Inhibitory Concentration Data

Average MIC data with growth details in various concentration ofceftriaxone and vancomycin combination of the present invention,ceftriaxone alone and vancomycin alone with following bacteria such asMSSA, Enterococcus, S. pneumoniae, Penicillin resistant streptococcuspneumoniae, MRSA. The observation for the combination of ceftriaxone andvancomycin used were successful in inhibiting bacteria in lesserconcentration than any of the salts alone, in wide range of bacteria asshown in table below.

Bacterial Susceptibility Test

Bacterial susceptibility test was performed for ceftriaxone andvancomycin, ceftriaxone alone and vancomycin alone on differentmicroorganisms. Different concentrations were selected mentioned to ashighest, high, low and lowest in data. Zone size was determined in mm.The activity of ceftriaxone and vancomycin was best seen in E. coli, B.subtillis, Klebsiella pneumoniae, Strptococus pneumoniae, andenterococus faecalis. The activity of combination observation was morepotent than single salt.

Stability Data

Stability study was done for ceftriaxone and vancomycin combination ofpresent invention for 6 months. All procedures were carried as perstandard testing procedures. It has been observed that the product isstable under accelerated conditions for 6 months.

TABLE 1 Average MIC data Concentrations S. aurens Streptococcus (μg/ml)Drug (MRSA) Enterococcus S. pneumoniae pneumoniae S. aurens 128Ceftriaxone No growth No growth No growth No growth No growth VancomycinNo growth No growth No growth No growth No growth Combination No growthNo growth No growth No growth No growth 64 Ceftriaxone No growth Nogrowth No growth No growth No growth Vancomycin No growth No growth Nogrowth No growth No growth Combination No growth No growth No growth Nogrowth No growth 32 Ceftriaxone Growth Found No growth No growth Nogrowth No growth Vancomycin No growth No growth No growth No growth Nogrowth Combination No growth No growth No growth No growth No growth 16Ceftriaxone Growth Found No growth No growth No growth No growthVancomycin No growth No growth No growth No growth No growth CombinationNo growth No growth No growth No growth No growth 8 Ceftriaxone GrowthFound No growth No growth No growth No growth Vancomycin No growth Nogrowth No growth No growth No growth Combination No growth No growth Nogrowth No growth No growth 4 Ceftriaxone Growth Found No growth Nogrowth No growth No growth Vancomycin No growth No growth No growth Nogrowth No growth Combination No growth No growth No growth No growth Nogrowth 2 Ceftriaxone Growth Found No growth No growth Growth Found Nogrowth Vancomycin Growth Found No growth No growth No growth GrowthFound Combination No growth No growth No growth No growth No growth 1Ceftriaxone Growth Found No growth No growth Growth Found No growthVancomycin Growth Found No growth No growth No growth Growth FoundCombination Growth Found No growth No growth No growth No growth 0.5Ceftriaxone Growth Found Growth Found No growth Growth Found GrowthFound Vancomycin Growth Found No growth No growth Growth Found GrowthFound Combination Growth Found No growth No growth No growth No growth0.25 Ceftriaxone Growth Found Growth Found Growth Found Growth FoundGrowth Found Vancomycin Growth Found Growth Found Growth Found GrowthFound Growth Found Combination Growth Found No growth No growth GrowthFound Growth Found 0.125 Ceftriaxone Growth Found Growth Found GrowthFound Growth Found Growth Found Vancomycin Growth Found Growth FoundGrowth Found Growth Found Growth Found Combination Growth Found GrowthFound Growth Found Growth Found Growth Found

TABLE 2 STABILITY STUDY Name of product: Ceftriaxone & vancomycin forinjection. 1.5 g Assay 90-110% 90-110% of labelled of labelled PeriodStorage Particulate amount of amount of (months) condition DescriptionIdentification matter BET Sterility PH(7.0-10.0) Ceftriaxone VancomycinInitial — Almost Passes Passes Passes Passes 8.85 100.3 99.7 white testtest test test colored powder 1 40° C./75% Almost Passes Passes PassesPasses 8.80 99.8 99.1 RH cream test test test test colored powder 2 40°C./75% A cream Passes Passes Passes Passes 8.76 99.1 98.3 RH coloredtest test test test powder 3 40° C./75% A cream Passes Passes PassesPasses 8.70 98.4 97.5 RH colored test test test test powder 6 40° C./75%A dark Passes Passes Passes Passes 8.62 97.4 96.6 RH cream test testtest test colored powder Packaging: glass vial

TABLE 3 Average cost comparison of Prior art v/s invention Prior artInvention Cost Saved Average hospitalization time 14 Averagehospitalization time 7 Rs-7000/- per days @ Rs-1000/day = Rs- days @Rs-1000/ day = Rs-7000/- hospital admission 14000/- Average cost ofVancomycin 1 g @ Average cost of Vancomycin Rs-14, 420/- Rs-750/- bd for14 days and Ceftriaxone@ Rs-700/-bd for 7 per treatment cost Ceftriaxone2 g @ bd for 14 days = 700 × 2 × 7 = Rs-9800/- days = 750 × 2 × 14 =Rs-21000/- + Total cost = Rs-9800/- 115 × 2 × 14 = Rs-3220/- Total cost= Rs-24,220/- Net saving to the patient per treatment is Rs-21,420/-

While the above description contains many specificities, these shouldnot be construed as limitations in the scope of the invention but asexemplifications of embodiments thereof. Many other variations arepossible. Accordingly, the scope of the invention should be determinednot by the embodiments illustrated, but by the appended claims and theirlegal equivalents.

1. A parenteral combination therapy for non-ocular infective conditionswith drug resistant bacterium, comprising a pharmaceutical composition,comprising: a. an antibacterially effective amount of a firstantibacterial agent, preferably a glycopeptide, acting as a first activeingredient, and b. an antibacterially effective amount of a secondantibacterial, preferably a cephalosporin, acting as a second activeingredient, wherein said first and said second antibacterial agents arepresent in predetermined weight ratios.
 2. A pharmaceutical compositionas claimed in claim 1, further comprising: a. a stable pharmaceuticallyacceptable excipient working as a chemical vector to mediate thecompatibility of said first antibacterial agent and said secondantibacterial agent for rendering stability to said composition, b. asuitable pharmaceutically acceptable sterile solvent vehicle with orwithout an additional excipient or a neutralising agent, said vehiclehaving solubilised and stabilised therein said first and secondantibacterial agents in an antibacterially effective amount, saidsolvent vehicle being preferably aqueous based, and c. at least oneexcipient selected from the group comprising diluents, antioxidants,preservatives, stabilizers, thickening agents, suspending agents,dispersing agents, solubilization agents, isotonic agents, bufferingagents, wetting agents, lubricants, emulsifiers, salts for influencingosmotic pressure, coloring agents, alcohols, other surfactants andconventional pharmaceutical additives.
 3. A pharmaceutical compositionas claimed in any of claims 1 and 2, wherein said first antibacterialagent is selected from a group comprising glycopeptides such asvancomycin, avoparcin, ramoplanin, teicoplanin, and daptomycin and thelike.
 4. A pharmaceutical composition as claimed in any of claims 1 to3, wherein said second antibacterial agent is selected form a groupcomprising beta-lactam antibacterials such as natural and syntheticpenicillin type agents including penam penicillins (such as benzylpenicillin, phenoxymethyl penicillin, coxacillin, nafcillin,methicillin, oxacillin, amoxycillin, temocillin, ticarcillin and thelike), penicillinase-stable penicillins, acylamino andcarboxypenicillins (such as piperacillin, aziocillin, meziocillin,carbenicillin, temocillin, ticarcillin and the like), and broaderspectrum penicillins (such as streptomycin, neomycin, framycetin,gentamicin, apramycin, amikacin, spectinomycin, amoxycillin, ampicillinand the like), cephalosporins (such as ceftriaxone, cefepime,ceftazidime, cefotaxime, cefuroxime and cefaclor).
 5. A pharmaceuticalcomposition as claimed in any of claims 1 to 4 wherein said firstantibacterial agent is a glycopeptide selected from the group consistingof avoparcin, ramoplanin, vancomycin, teicoplanin, daptomycin, andpreferably vancomycin or a pharmaceutically acceptable salt thereof. 6.A pharmaceutical composition as claimed in any of claims 1 to 5 whereinsaid pharmaceutically acceptable salt of said vancomycin is vancomycinhydrochloride.
 7. A pharmaceutical composition as claimed in any ofclaims 1, 2, 3, 5, and 6, wherein said first antibacterial agent ispresent in said composition at a concentration in the range from about 1mg/ml to about 100 mg/ml, preferably in the range from about 5 mg/ml toabout 75 mg/ml, and more preferably in the range of about 10 mg/ml toabout 50 mg/ml.
 8. A pharmaceutical composition as claimed in any ofclaims 1, 2 and 4 wherein said second antibacterial agent is acephalosporin and is elected from a group of cephazoline, cefuroxime,cefotaxime, cefpirome, cefepime, ceftriaxone, ceftazidime, andcefoperazone.
 9. A pharmaceutical composition as claimed in any ofclaims 1, 2, 4, and 8, wherein said second second antibacterial agent isceftriaxone or a pharmaceutically acceptable salt thereof.
 10. Apharmaceutical composition as claimed in claim 9 wherein saidpharmaceutically acceptable salt of said ceftriaxone is ceftriaxonesodium.
 11. A pharmaceutical composition as claimed in any of claims 1,2, 4, 8, 9, and 10 wherein said second antibacterial agent is present insaid composition at a concentration in the range from about 1 mg/ml toabout 200 mg/ml, preferably in the range from about 5 mg/ml to about 150mg/ml, and more preferably in the range from about 10 mg/ml to about 100mg/ml.
 12. A pharmaceutical composition as claimed in any of claims 1 to11 wherein said predetermined weight ratio of said first antibacterialagent to said second antibacterial agent is in the range from about 1:4to about 4:1 respectively, probably in the range from about 1:3 to about3:1 respectively, more preferably in the range from about 1:2 to about2:1 respectively.
 13. A pharmaceutical composition as claimed in claim2, wherein when making said suitable solvent vehicle, a neutralisingagent is optionally mixed with a desired quantity of water for injectionand aminocarboxylic acid chelating agent such asethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaaceticacid (DTPA), hydroxyethylenediaminetriaceti-c acid (HEDTA),nitrilotriacetic acid (NTA) and neutralized with sodium bicarbonate orL-arginine or other suitable agents, to bring the concentration of thesolution within the preferred range of about 10 to about 100 mg/ml, morepreferably within the range of about 20 to about 90 mg/ml, and mostpreferably within the range of about 40 to about 80 mg/ml or anycombination or sub combination of ranges therein.
 14. A pharmaceuticalcomposition as claimed in any of claims 1 to 13 wherein said compositionis in the form of a sterile powder reconstituted by addition of acompatible reconstitution diluent prior to parenteral administration.15. A pharmaceutical composition as claimed in any of claims 1 to 14wherein said composition can be reconstituted by addition of acompatible reconstitution diluent vehicle prior to parenteraladministration and is made chemically by use of the chemical vectormediated compatibility technology.
 16. A pharmaceutical composition asclaimed in any of claims 1 to 15, wherein said first and secondantibacterial agents are present in said composition in any formcomprising particles, powders, granules, nanoparticles,microparticulates, microspheres, or lyphilised form and the like.
 17. Apharmaceutical composition as claimed in any of claims 1 to 16, whereina pharmaceutically effective unit/multiple dose of said combination, inthe form of the concentrate of said dose, wherein said dose is providedin a sealed airtight container which is selected from the groupconsisting of a vial, a mono vial, an ampoule, a syringe, a packet, apouch and an auto-injector, wherein said container has a head spacevolume sufficient for introduction of appropriate volume of an aqueoussolvent sufficient to form a unit dose in the form of an appropriatereconstituted solution of said combination.
 18. A pharmaceuticalcombination, as claimed in any of claims 1 to 17, wherein saidcombination is provided in the form of a dry sterilized powder, in saidsealed airtight container to form a pharmaceutically acceptable requiredfixed dose combination for reconstitution prior to intramuscular orintravenous administration for the treatment of the non-ocular infectiveconditions with drug resistant bacterium, wherein the combination dosageform after reconstitution is a sterile solution with the pH of theconstituted solution being in the range from about 7 to about
 9. 19. Apharmaceutical composition, as claimed in any of claims 1 to 18, whereinsaid combination is provided in said sealed container wherein said vialis made of transparent glass and is capped with appropriate halogenatedstopper and seal, and is used for reconstitution for intramuscular orintravenous administration for the treatment of the non-ocular infectiveconditions with drug resistant bacterium in mammals.
 20. Apharmaceutical composition, as claimed in any of claims 1 to 19, whereinsaid combination is provided in a reconstituted form in said sealedairtight container which is selected from said group consisting of saidvial, said mono vial, said ampoule, said syringe, said packet, saidpouch, and said auto-injector, wherein interior space of said containercomprises a fill volume occupied by said composition in reconstitutedform and a head space volume occupied aseptically by aninert-gas-limited microatmosphere, which comprises essentially one ormore inert gas which is selected from the group consisting of noblegases and nitrogen; preferably nitrogen, volume of said nitrogen gasbeing not more than 5% of said head space volume, and wherein ratio ofsaid fill volume to said head space volume is not less than 1:1.
 21. Apharmaceutical composition, as claimed in any of claims 1 to 20 whereinsaid first antibacterial agent and said second antibacterial agent arepresent in pharmaceutically effective total amount corresponding to asingle unit or multiple dose, in said sealed container, filledaseptically under inert gas blanket.
 22. A process for preparing apharmaceutical composition suitable for parenteral combination therapyfor non-ocular infective conditions with drug resistant bacterium,comprising the steps of: a. sterile filling/blending said first and saidsecond antibacterial agents, wherein said first antibacterial agent,being a first antibacterial active ingredient, is vancomycin or a firstpharmaceutically acceptable salt thereof, such as vancomycinhydrochloride; wherein said second antibacterial agent, being a secondactive ingredient, is ceftriaxone or a second pharmaceuticallyacceptable salt thereof, such as ceftriaxone sodium; b. adding aparticulate formation/precipitation inhibitor present in the form of achemical vector; c. continuing said sterile filling/blending operationfor a period of about 1 hour to about 8 hours; d. proportioning thesterile fill/blend of step (a) to get desired pharmaceutically effectivedose in weight ratio of said first antibacterial agent to said secondantibacterial agent in the range from about 1:4 to about 4:1respectively; preferably in the range from about 1:3 to about 3:1respectively; and more preferably in the range from about 1:2 to about2:1 respectively; the range of said chemical vector being in the rangefrom about 10% to about 40% of the total weight of the blended/filledcomposition; and e. e. capping aseptically with pre/post inert gassing.23. A method of treatment and/or prevention of a non-ocular infectivecondition caused by drug resistant bacterium, said method comprising thestep of parenterally administering the pharmaceutical composition ofclaim 1 in an antibacterially effective amount.
 24. A pharmaceuticalcomposition suitable for parenteral combination therapy for non-ocularinfective condition with drug resistant bacterium substantially asherein described and illustrated.
 25. A process for preparing apharmaceutical composition suitable for parenteral combination therapyfor non-ocular infective conditions with drug resistant bacteriumsubstantially as herein described and illustrated.
 26. A method oftreatment and/or prevention of a non-ocular infective condition causedby drug resistant bacterium, substantially as herein described andillustrated.